Talk:Astex Pharmaceuticals

Private?
Part of article says ASTX is private, and part of article gives Nasdaq ticker symbol. Resolve? 71.139.166.154 (talk) 00:33, 7 August 2013 (UTC)

External links modified
Hello fellow Wikipedians,

I have just modified 2 one external links on Astex. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
 * Added archive https://web.archive.org/web/20150101213835/https://opencorporates.com/officers/33306565 to https://opencorporates.com/officers/33306565
 * Added tag to http://investor.astx.com/releasedetail.cfm?ReleaseID=601567
 * Added archive https://web.archive.org/web/20061018140001/http://pharmalicensing.com/articles/disp/1054649550_3edcacceb756b to http://pharmalicensing.com/articles/disp/1054649550_3edcacceb756b

When you have finished reviewing my changes, please set the checked parameter below to true or failed to let others know (documentation at ).

Cheers.— InternetArchiveBot  (Report bug) 07:37, 20 October 2016 (UTC)

Removal of Logo graphic
@Scitribe removed the logo File:Logo astex.jpg with the edit comment "Removed logo as no longer required". Wondering what rationale is behind this and whether others agree. Thanks. --User:Ceyockey ( talk to me ) 01:20, 18 April 2021 (UTC)

Article requires updating

 * What I think should be changed (include citations):

Headquarters: The item "US Corporate and Clinical Development headquarters in Pleasanton, California, USA (Astex Pharmaceuticals Inc.)" should be deleted


 * Why it should be changed:

This part of the company has been restructured


 * References supporting the possible change (format using the "cite" button):


 * What I think should be changed (include citations):

Key people: The following sentence should be deleted:

Martin Buckland (President and Chief Corporate Officer, Astex Pharmaceuticals Inc.), Harold N. Keer (Chief Medical Officer, Astex Pharmaceuticals Inc.)


 * Why it should be changed:

These individuals are no longer employees of Astex

170.85.58.100 (talk) 13:55, 18 June 2024 (UTC)
 * References supporting the possible change (format using the "cite" button):


 * What I think should be changed (include citations):

History:

The first paragraph should be edited to read as follows:

Astex was founded as “Astex Technology Limited” in 1999 in Cambridge, UK, to pioneer a novel approach to small molecule drug discovery known as ‘fragment-based drug discovery’ (FBDD), a term first coined by Astex scientists (cite ref: https://pubmed.ncbi.nlm.nih.gov/12650591/) that is now a well recognised approach to small molecule drug discovery across the pharmaceutical industry. Astex’s proprietary drug discovery platform, Pyramid™, can effectively identify novel small molecule drugs for key disease targets. Originally funded by venture capital, from a number of investors including Abingworth, Advent international, Oxford Bioscience Partners, Apax Partners and Gimv. Astex established strategic partnerships with major pharmaceutical companies including Novartis, Janssen Pharmaceuticals, AstraZeneca and GlaxoSmithKline.


 * Why it should be changed:

To include a reference to the first time the term 'fragment-based drug discovery' was used


 * References supporting the possible change (format using the "cite" button):

https://pubmed.ncbi.nlm.nih.gov/12650591/ 170.85.58.100 (talk) 13:55, 18 June 2024 (UTC)


 * What I think should be changed (include citations):

History:

The second paragraph should be edited to read as follows:

In 2005, the Company changed its name to Astex Therapeutics Limited when its first product entered clinical development. In 2011, Astex Therapeutics Limited and SuperGen, Inc. (US) merged. Following the acquisition, SuperGen, Inc., changed its name to Astex Pharmaceuticals, Inc., and began trading under the ticker symbol ASTX on NASDAQ. The combined Astex entities were subsequently acquired by Otsuka Pharmaceutical in October 2013 for around USD $900 million, and operates as part of the Otsuka group as wholly-owned subsidiaries. In January 1, 2024, Astex Pharmaceuticals, Inc., became part of Taiho Oncology, Inc., as part of an internal re-organisation to consolidate oncology clinical development within the Otsuka group. This internal change did not impact the drug discovery research operation of Astex Pharmaceuticals (UK), based in Cambridge, UK, which continues to operate as ‘Astex’.


 * Why it should be changed:

The additional sentence describes the reorganisation of the company from January 1, 2024 which is the main reason for the update.


 * References supporting the possible change (format using the "cite" button):


 * What I think should be changed (include citations):

The following wording should be delete:

Astex currently operates from two sites: ·       European Corporate and Research headquarters in Cambridge, UK (Astex Therapeutics Limited) ·       US Corporate and Clinical Development headquarters in Pleasanton, California, USA (Astex Pharmaceuticals Inc.)


 * Why it should be changed:

As a result of the reorganisation, the company no longer operates from two sites


 * References supporting the possible change (format using the "cite" button):


 * What I think should be changed (include citations):

Research and Development:

The second and third paragraph should be amended to read as follows:

Astex’s Pyramid™ platform is focused on the rational design of novel small molecule targeted therapies. Its structure based drug discovery approach is based on the use of biophysical techniques, principally X-ray crystallography and cryo-electron microscopy (cryo-EM), to screen and identify very small, low molecular weight fragments of drugs binding into the disease target of interest. Astex uses its knowledge of the 3-dimensional structure of the binding interaction between the compound and the target to design and grow from the initial fragment, adding further functionality to improve the affinity and selectivity of the binding interaction so that the final drug compound interacts optimally with the disease target and modulates its activity either through inhibition or activation.

In 2020, Astex and Taiho Pharmaceutical Co., Ltd. entered into a drug discovery collaboration with Merck & Co., Inc., Kenilworth, New Jersey, USA (known as MSD outside the USA and Canada) focused on the oncogene KRas,. This collaboration was extended in 2021. In 2023 Astex announced a further collaboration with MSD to identify small molecule candidates with activity towards the tumour suppressor protein p53 for the treatment of cancer (ref: https://astx.com/astex-expands-drug-discovery-collaboration-with-msd/).


 * Why it should be changed:

As an update on further collaborations that the company has enetered into - with a reference to the press release at the end of the third paragraph


 * References supporting the possible change (format using the "cite" button):

https://astx.com/astex-expands-drug-discovery-collaboration-with-msd/ 170.85.58.100 (talk) 13:55, 18 June 2024 (UTC)


 * What I think should be changed (include citations):

Clinical pipeline:

The second paragraph should be edited to read as follows.

Several compounds from drug discovery collaborations with Astex have been advanced by Astex’s biopharma partners into clinical trials and onto the market, including ribociclib (brand name “Kisqali”), a CDK4/CDK6 inhibitor discovered in collaboration with Novartis that was granted approval in the US and EU in 2017 for the treatment of breast cancer. Astex’s second partnered product to be approved is Erdafitinib (brand name “Balversa”) an FGFR inhibitor that was discovered with Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), and received FDA market approval for the treatment of metastatic urothelial carcinoma in 2019, subsequent to an original collaboration on FGFR inhibitors between Astex and Newcastle University Astex’s third partnered product to reach approval is TruqapTM (capivasertib) which was discovered by AstraZeneca subsequent to its collaboration with Astex and Astex’s earlier collaboration with the Institute for Cancer Research and Cancer Research UK. AstraZeneca began to develop the drug as a potential treatment for various forms of cancer after its discovery in 2010. Truqap (capivasertib) in combination with Faslodex (fulvestrant) was approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN) in 2023 (cite ref: https://www.astrazeneca.com/media-centre/press-releases/2023/truqap-approved-in-us-for-hr-plus-breast-cancer.html ).


 * Why it should be changed:

To update with new information on the most recent drug approval and to correct errors in the existing text


 * References supporting the possible change (format using the "cite" button):

https://www.astrazeneca.com/media-centre/press-releases/2023/truqap-approved-in-us-for-hr-plus-breast-cancer.html 170.85.58.100 (talk) 13:55, 18 June 2024 (UTC)


 * What I think should be changed (include citations):


 * Why it should be changed:

170.85.58.100 (talk) 13:55, 18 June 2024 (UTC)
 * References supporting the possible change (format using the "cite" button):

170.85.58.100 (talk) 13:55, 18 June 2024 (UTC)